Dyslipidaemia after switch to tenofovir alafenamide (TAF)-based cART regimens in a cohort of HIV-positive patients: what clinical relevance?
L GazzolaGianmarco TagliaferriA De BonaD MondatoreC BorsinoT BiniGiulia Carla MarchettiAntonella d'Arminio MonfortePublished in: HIV medicine (2020)
Switching from TDF to TAF affects lipid parameters, and data from real life suggest a clinical relevance of this worsening that often leads clinicians to implement lifestyle/therapeutic interventions.
Keyphrases
- hiv positive
- antiretroviral therapy
- end stage renal disease
- men who have sex with men
- ejection fraction
- physical activity
- newly diagnosed
- chronic kidney disease
- south africa
- metabolic syndrome
- cardiovascular disease
- prognostic factors
- peritoneal dialysis
- palliative care
- weight loss
- type diabetes
- human immunodeficiency virus
- artificial intelligence